Program
garsorasib
Also written as “D-1553”, “IN10018 in combination with D-1553” and “D-1553 Tablet”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InventisBio | 62 open or running | phase 2since Sep 27, 2020 | Sep 27, 2020 | Dec 31, 2027phase 2 · NCT05379946 |
| InxMed (Shanghai) | 11 open or running | phase 3since Aug 29, 2025 | Aug 29, 2025 | Sep 2028phase 3 · NCT07174908 |
| Sino Biopharmaceutical | 11 open or running | phase 3since Mar 3, 2024 | Mar 3, 2024 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2020First study: phase 2 study in Solid Tumor, AdultNew to InventisBioInventisBio · NCT04585035 · 180 enrolled · United States, Australia, Korea, Republic of and more
- May 13, 20222 phase 2 studiesInventisBio · NCT05383898, NCT05379946
- Aug 5, 2022Phase 2 study in NSCLCInventisBio · NCT05492045 · 22 enrolled · China
- Oct 17, 2023Phase 1 study in Healthy MaleInventisBio · NCT06105255 · 45 enrolled · China
- Nov 27, 2023Phase 1 study in Mass Balance StudyInventisBio · NCT06233916 · 8 enrolled · China
- Mar 3, 2024Sino Biopharmaceutical's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06300177 · 522 planned · China
- Aug 29, 2025InxMed (Shanghai)'s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to InxMed (Shanghai)InxMed (Shanghai) · NCT07174908 · 400 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Solid TumorInventisBio · NCT05379946
- Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07174908Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | InxMed (Shanghai) | Sep 2028 | 400 |
| NCT06300177Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sino Biopharmaceutical | Oct 2026 | 522 |
| NCT06233916Mass Balance Study · China | 1 | Completed | InventisBio | Jan 3, 2024 | 8 |
| NCT06105255Healthy Male · China | 1 | Completed | InventisBio | Feb 2, 2024 | 45 |
| NCT05492045NSCLC · China | 2 | Terminated | InventisBio | Jun 14, 2024 | 22 |
| NCT05383898NSCLC · China | 2 | Completed | InventisBio | Nov 17, 2023 | 225 |
| NCT05379946Solid Tumor · China | 2 | Active, not recruiting | InventisBio | Dec 31, 2027 | 92 |
| NCT04585035Solid Tumor, Adult · United States, Australia, Korea, Republic of and more | 2 | Active, not recruiting | InventisBio | Apr 30, 2024 | 180 |
How it is read
Names in the registry
- “D-1553”, 5 entries
- “IN10018 in combination with D-1553”, 1 entry
- “D-1553 Tablet”, 1 entry
- “[14C] D-1553”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.